



General Pathology


European Society of Pathology

 Sat, March 16

 7:00 PM - 10:00
PM

 National Harbor
6

 Companion
Society Meetings

 CME: 3 • SAM: 3

Description

Recent Advances and Updates in Histopathology

The 1st European Society of Pathology Companion Meeting will focus on recent advances and updates in histopathology of melanoma, endometrial carcinoma, renal and thyroid tumors, and chronic liver disease. The chosen topics will be presented by expert faculty with diagnostic and research expertise in these areas. Although conventional histomorphology remains the gold standard in the interpretation of solid tumors, molecular approaches have become crucial in solving many scientific and diagnostic challenges. The use of morphologic criteria alone is not sufficient to recognize tumor entities and the importance of new ancillary molecular techniques for optimizing the diagnostic procedure will be emphasized in the course. In addition, the most common chronic liver disease nonalcoholic fatty liver disease - will be discussed under the light of its pathophysiology and updates in classification and how these impact on biomarkers development and clinical trial design will be highlighted. Liver pathology in inflammatory bowel disease will be reviewed and the role of liver biopsy in the context will be underlined.

Course Learning Objectives

Upon completion of this educational activity, the learner will be able to:

- Appreciate the renal tumours with clear/light-staining cytoplasm include well established and novel/emerging tumour entities and discuss their differential diagnosis, immunohistochemistry and molecular background.
- Recognise the importance of the new targeted treatments and immunotherapy for patients with melanoma and describe how to predict progression and predict or monitor therapeutic response in melanoma.
- Describe the microscopic and molecular basis of endometrial carcinoma classification and discuss the diagnostic criteria, differential diagnosis and prognostic implications of different types of endometrial carcinoma.
- Evaluate the progress in separating low-grade from high-grade malignancy in thyroid tumours using morphological, immunohistochemical and molecular data.
- Describe the broad histopathological spectrum of NAFLD based on disease pathophysiology and discuss how this new information impacts NAFLD classification, the development of biomarkers and clinical trials.
- Justify the role of liver biopsy and discuss liver pathology in inflammatory bowel disease

Continuing Medical Education and Continuing Certification

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and The European Society of Pathology. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide

continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC).

Physicians can earn a maximum of 3.0 SAM credit hours.

Moderator(s)



Moderator

Dina Tiniakos, MD, Aretaieion Hospital, National & Kapodistrian University of Athens, Athens, Greece and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK



Co-Moderator

Pierre Bedossa, MD, LiverPat, Paris, France and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Presentations

Introduction

Dina Tiniakos, MD, Aretaieion Hospital, National & Kapodistrian University of Athens, Athens, Greece and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK >

Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: A nonexisting or new tumour entity?

Holger Moch, MD, University Hospital Zürich, Zürich, Switzerland >

Tissue markers of prognosis and therapy in melanoma

Daniela Massi, MD, University of Florence >

Classification of endometrial carcinoma: Pathological and molecular perspectives

Xavier Matias-Guiu, MD, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, Lleida, Spain >

Recent advances in surgical pathology of thyroid tumors

Manuel Sobrinho-Simões, MD, PhD, University of Porto / IPATIMUP >

Changing concepts and classification in non-alcoholic steatohepatitis (NASH)



Pierre Bedossa, MD, LiverPat, Paris, France and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Update on liver pathology in inflammatory bowel disease



Dina Tiniakos, MD, Aretaieion Hospital, National & Kapodistrian University of Athens, Athens, Greece and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK